title: High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.
abstract: Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy. In an attempt to simplify post-remission therapy, deliver adequate dose of anthracycline and reduce treatment related toxicity, we entered 26 consecutively newly diagnosed, previously untreated APL patients in a pilot treatment program consisting of concurrent induction using idarubicin/ATRA followed by an exclusive outpatient post-remission therapy using single dose of idarubicin and intermittent ATRA, every 4 weeks. Of 25 evaluable patients, two (8%) died early during induction due to hemorrhagic complications, and 23 (92%) achieved complete remission. Overall survival at 4.2 years was 90% (CI 76.4-100), and 3.6 years disease-free survival was 78% (CI 60.6-95.4). The treatment outcome of this program is encouraging; however, the result of this study needs to be validated in larger cohort of patients and optimally in a randomized comparison with other current post-remission approaches.
authors: King Faisal Cancer Centre, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh, 11211, Saudi Arabia. maljurf@kfshrc.edu.sa
authors: M
authors: M
authors: Aljurf
authors: F
authors: F
authors: Al Qurashi
authors: F
authors: F
authors: Al Mohareb
authors: E
authors: E
authors: Sahovic
authors: F
authors: F
authors: Al Sharif
authors: H
authors: H
authors: Al Zahrani
authors: A
authors: A
authors: Al Shanqeeti
authors: T
authors: T
authors: Owaidah
authors: A
authors: A
authors: Iqbal
authors: S Z A
authors: SZ
authors: Zaidi
authors: Z A
authors: ZA
authors: Nurgat
authors: M
authors: M
authors: Sanz
authors: N
authors: N
authors: Chaudhri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000032:analysis / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D053208:Kaplan-Meier Estimate; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: C026912:cryoprecipitate coagulum; D014212:Tretinoin; D003907:Dexamethasone; D005169:Factor VIII; D005340:Fibrinogen; D015255:Idarubicin